🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hongjing Zang

Central South University

ORCID: 0009-0001-9713-6523

Also affiliated with Changsha Medical University, Hunan Cancer Hospital, Second Xiangya Hospital of Central South University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)”.

Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Cancer(2020)10.1002/cncr.32744
N/A
0DataRank · unranked
48 citations

Guoqing Qian, Dan Zong, Songqing Fan, Taofeek K. Owonikoko, Suresh S. Ramalingam +2 more

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Cancer Research(2021)10.1158/0008-5472.can-21-0556
N/A
0DataRank · unranked
67 citations

Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang +7 more

Data from Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

(2023)10.1158/0008-5472.c.6513256.v1
N/A
0DataRank · unranked
0 citations

Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang +7 more